Heterogeneity of kinase inhibitor resistance mechanisms in GIST

Patrick Therasse, Axel Le Cesne, Martine Van Glabbeke, Jaap Verweij, Ian Judson, EORTC Soft Tissue and Bone Sarcoma Group, RECIST vs. WHO: Prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma European Journal of Cancer. ,vol. 41, pp. 1426- 1430 ,(2005) , 10.1016/J.EJCA.2005.04.005

Maria Debiec-Rychter, Jan Cools, Herlinde Dumez, Raf Sciot, Michel Stul, Nicole Mentens, Hilde Vranckx, Bartosz Wasag, Hans Prenen, Johannes Roesel, Anne Hagemeijer, Allan Van Oosterom, Peter Marynen, Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants Gastroenterology. ,vol. 128, pp. 270- 279 ,(2005) , 10.1053/J.GASTRO.2004.11.020

Narasimhan P. Agaram, Ann Baren, Knarik Arkun, Ronald P. DeMatteo, Peter Besmer, Cristina R. Antonescu, Comparative ultrastructural analysis and KIT/PDGFRA genotype in 125 gastrointestinal stromal tumors. Ultrastructural Pathology. ,vol. 30, pp. 443- 452 ,(2006) , 10.1080/01913120600854186

Narasimhan P. Agaram, Peter Besmer, Grace C. Wong, Tianhua Guo, Nicholas D. Socci, Robert G. Maki, Diann DeSantis, Murray F. Brennan, Samuel Singer, Ronald P. DeMatteo, Cristina R. Antonescu, Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors Clinical Cancer Research. ,vol. 13, pp. 170- 181 ,(2007) , 10.1158/1078-0432.CCR-06-1508

Katherine L. Osusky, Dennis E. Hallahan, Allie Fu, Fei Ye, Yu Shyr, Ling Geng, The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis. ,vol. 7, pp. 225- 233 ,(2004) , 10.1007/S10456-004-3149-Y

Hans Prenen, Jan Cools, Nicole Mentens, Cedric Folens, Raf Sciot, Patrick Schöffski, Allan Van Oosterom, Peter Marynen, Maria Debiec-Rychter, Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clinical Cancer Research. ,vol. 12, pp. 2622- 2627 ,(2006) , 10.1158/1078-0432.CCR-05-2275

Christopher D.M. Fletcher, Heikki Joensuu, George D. Demetri, Margaret von Mehren, Charles D. Blanke, Annick D. Van den Abbeele, Burton Eisenberg, Peter J. Roberts, Michael C. Heinrich, David A. Tuveson, Samuel Singer, Milos Janicek, Jonathan A. Fletcher, Stuart G. Silverman, Sandra L. Silberman, Renaud Capdeville, Beate Kiese, Bin Peng, Sasa Dimitrijevic, Brian J. Druker, Christopher Corless, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England Journal of Medicine. ,vol. 347, pp. 472- 480 ,(2002) , 10.1056/NEJMOA020461

Christopher L. Corless, Laura McGreevey, Andrea Haley, Ajia Town, Michael C. Heinrich, KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. American Journal of Pathology. ,vol. 160, pp. 1567- 1572 ,(2002) , 10.1016/S0002-9440(10)61103-0

Michael C Heinrich, Charles D Blanke, Brian J Druker, Christopher L Corless, Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies Journal of Clinical Oncology. ,vol. 20, pp. 1692- 1703 ,(2002) , 10.1200/JCO.20.6.1692

Marco Seandel, Jinru Shia, Irina Linkov, Robert G. Maki, Cristina R. Antonescu, Jakob Dupont, The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects. Clinical Cancer Research. ,vol. 12, pp. 6203- 6204 ,(2006) , 10.1158/1078-0432.CCR-06-1292